The FDA has granted full approval for Novavax's COVID-19 vaccine, but with restrictions. Discover the details now.

BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The approval of Nuvaxovid for use in older and high-risk adults will generate ...

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This ...

Live Updates Live Coverage Has Ended Markets Turn Positive 1:37 pm by The stock market has managed to crawl its way back ...

Tesla's Chinese rival Xiaomi announced its electric SUV set to compete with Tesla's Model Y will be launched Thursday. TXNM ...

Live Updates Live Coverage Updates appear automatically as they are published. Retail Earnings on Deck 10:28 am by With the ...

President Donald Trump's tax cut and spending bill faces a critical stress test on Wednesday as Republicans in the U.S. House ...

In the options pits, NVAX has already seen quadruple the overall options volume it typically sees in an entire session, with ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...